Mark S. Schroeder's most recent trade in Laboratory Corp. Of America Holdings was a trade of 4,840 Common Stock done . Disclosure was reported to the exchange on March 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2025 | 4,840 | 9,800 (0%) | 0% | 0 | Common Stock | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Sale of securities on an exchange or to another person at price $ 231.67 per share. | 27 Mar 2025 | 2,635 | 4,960 (0%) | 0% | 231.7 | 610,450 | Common Stock |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 231.67 per share. | 27 Mar 2025 | 2,205 | 7,595 (0%) | 0% | 231.7 | 510,832 | Common Stock |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Sale of securities on an exchange or to another person at price $ 249.23 per share. | 28 Feb 2025 | 5,339 | 4,960 (0%) | 0% | 249.2 | 1,330,639 | Common Stock |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 131.43 per share. | 28 Feb 2025 | 3,903 | 10,299 (0%) | 0% | 131.4 | 512,971 | Common Stock |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 3,903 | 0 | - | - | Non-qualified Stock Options | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 7,300 | 7,300 | - | - | Non-qualified Stock Options | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 2,420 | 5,061 | - | - | Restricted Stock Unit | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2025 | 473 | 6,530 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2025 | 473 | 4,588 | - | - | Restricted Stock Unit | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 245.14 per share. | 11 Feb 2025 | 134 | 6,396 (0%) | 0% | 245.1 | 32,849 | Common Stock |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 743 | 3,322 | - | - | Restricted Stock Unit | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 743 | 5,779 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 517 | 6,086 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 517 | 2,805 | - | - | Restricted Stock Unit | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 247.74 per share. | 06 Feb 2025 | 210 | 5,569 (0%) | 0% | 247.7 | 52,025 | Common Stock |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 164 | 6,104 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 164 | 2,641 | - | - | Restricted Stock Unit | |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 246.27 per share. | 06 Feb 2025 | 146 | 5,940 (0%) | 0% | 246.3 | 35,955 | Common Stock |
| Labcorp | Mark S. Schroeder | EVP, Pres Diagnostics & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 246.28 per share. | 06 Feb 2025 | 47 | 6,057 (0%) | 0% | 246.3 | 11,575 | Common Stock |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Sale of securities on an exchange or to another person at price $ 217.29 per share. | 01 Apr 2024 | 6,477 | 5,036 (0%) | 0% | 217.3 | 1,407,387 | Common Stock |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Sale of securities on an exchange or to another person at price $ 218.45 per share. | 07 Mar 2024 | 5,048 | 5,036 (0%) | 0% | 218.5 | 1,102,736 | Common Stock |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 2,119 | 0 | - | - | Non-qualified Stock Options | |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.09 per share. | 07 Mar 2024 | 2,119 | 10,084 (0%) | 0% | 117.1 | 248,114 | Common Stock |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2024 | 472 | 8,091 (0%) | 0% | - | Common Stock | |
| Labcorp | Schroeder Mark | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2024 | 472 | 15,621 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 227.45 per share. | 11 Feb 2024 | 126 | 7,965 (0%) | 0% | 227.5 | 28,659 | Common Stock |
| Labcorp | Schroeder Mark | EVP, Pres Diagnostics & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 6,900 | 6,900 | - | - | Non-qualified Stock Options | |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 2,230 | 16,773 | - | - | Restricted Stock Unit | |
| Labcorp | Schroeder Mark | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 517 | 7,638 (0%) | 0% | - | Common Stock | |
| Labcorp | Schroeder Mark | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 517 | 16,256 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 163 | 16,093 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 163 | 7,663 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.71 per share. | 06 Feb 2024 | 138 | 7,500 (0%) | 0% | 223.7 | 30,872 | Common Stock |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.70 per share. | 06 Feb 2024 | 44 | 7,619 (0%) | 0% | 223.7 | 9,843 | Common Stock |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 495 | 14,543 | - | - | Restricted Stock Unit | |
| Labcorp | Schroeder Mark | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 495 | 7,253 (0%) | 0% | - | Common Stock | |
| Labcorp | Schroeder Mark | EVP, Pres Diagnostics & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 221.54 per share. | 02 Feb 2024 | 132 | 7,121 (0%) | 0% | 221.5 | 29,243 | Common Stock |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 11,648 | 14,769 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Sale of securities on an exchange or to another person at price $ 216.77 per share. | 18 May 2023 | 1,500 | 6,687 (0%) | 0% | 216.8 | 325,155 | Common Stock |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 1,500 | 1,900 | - | - | Non-qualified Stock Options | |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 130.60 per share. | 18 May 2023 | 1,500 | 8,187 (0%) | 0% | 130.6 | 195,900 | Common Stock |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 1,400 | 1,400 | - | - | Non-qualified Stock Options | |
| Labcorp | Mark Schroeder | EVP, Pres Diagnostics & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 440 | 3,121 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2023 | 6,763 | 13,450 (0%) | 0% | 0 | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Sale of securities on an exchange or to another person at price $ 225.81 per share. | 30 Mar 2023 | 3,897 | 6,687 (0%) | 0% | 225.8 | 879,982 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.70 per share. | 30 Mar 2023 | 2,866 | 10,584 (0%) | 0% | 224.7 | 643,990 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Sale of securities on an exchange or to another person at price $ 247.63 per share. | 14 Feb 2023 | 309 | 6,687 (0%) | 0% | 247.6 | 76,518 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 423 | 7,110 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 423 | 2,681 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Payment of exercise price or tax liability using portion of securities received from the company at price $ 248.13 per share. | 11 Feb 2023 | 114 | 6,996 (0%) | 0% | 248.1 | 28,287 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 4,400 | 4,400 | - | - | Non-qualified Stock Options | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 1,390 | 3,104 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Sale of securities on an exchange or to another person at price $ 243.01 per share. | 07 Feb 2023 | 409 | 6,687 (0%) | 0% | 243.0 | 99,391 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2023 | 560 | 7,247 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2023 | 560 | 1,714 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.50 per share. | 04 Feb 2023 | 151 | 7,096 (0%) | 0% | 244.5 | 36,920 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 443 | 2,274 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 443 | 7,130 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Sale of securities on an exchange or to another person at price $ 253.90 per share. | 02 Feb 2023 | 324 | 6,687 (0%) | 0% | 253.9 | 82,264 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.99 per share. | 02 Feb 2023 | 119 | 7,011 (0%) | 0% | 255.0 | 30,344 | Common Stock |
| German American Bancorp Inc | Mark A. Schroeder | Director, EXECUTIVE CHAIRMAN | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2022 | 7,568 | 134,018 (0%) | 0% | - | Common Stock | |
| German American Bancorp Inc | Mark A. Schroeder | Director, EXECUTIVE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 689 | 141,586 (0%) | 0% | - | Common Stock | |
| German American Bancorp Inc | Mark A. Schroeder | Director, EXECUTIVE CHAIRMAN | Purchase of securities on an exchange or from another person at price $ 36.09 per share. | 19 Dec 2022 | 658 | 134,676 (0%) | 0% | 36.1 | 23,748 | Common Stock |
| German American Bancorp Inc | Mark A. Schroeder | Director, EXECUTIVE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 10,598 | 140,897 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 2,010 | 4,744 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 2,010 | 7,139 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Payment of exercise price or tax liability using portion of securities received from the company at price $ 274.84 per share. | 05 Nov 2021 | 899 | 6,240 (0%) | 0% | 274.8 | 247,081 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Sale of securities on an exchange or to another person at price $ 251.88 per share. | 30 Mar 2021 | 667 | 5,006 (0%) | 0% | 251.9 | 168,004 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2021 | 2,413 | 6,752 (0%) | 0% | 0 | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Payment of exercise price or tax liability using portion of securities received from the company at price $ 251.58 per share. | 27 Mar 2021 | 1,079 | 5,673 (0%) | 0% | 251.6 | 271,455 | Common Stock |
| German American Bancorp Inc | Mark A. Schroeder | Director, CHAIRMAN, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 7,357 | 129,644 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 283 | 6,754 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 283 | 4,605 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 234 | 7,037 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 234 | 4,386 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Sale of securities on an exchange or to another person at price $ 237.06 per share. | 12 Feb 2021 | 103 | 4,424 (0%) | 0% | 237.1 | 24,417 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Sale of securities on an exchange or to another person at price $ 237.06 per share. | 12 Feb 2021 | 85 | 4,339 (0%) | 0% | 237.1 | 20,150 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Payment of exercise price or tax liability using portion of securities received from the company at price $ 238.26 per share. | 12 Feb 2021 | 78 | 4,527 (0%) | 0% | 238.3 | 18,584 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Payment of exercise price or tax liability using portion of securities received from the company at price $ 238.27 per share. | 12 Feb 2021 | 64 | 4,322 (0%) | 0% | 238.3 | 15,249 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 560 | 4,509 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 560 | 7,271 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Sale of securities on an exchange or to another person at price $ 225.85 per share. | 04 Feb 2021 | 203 | 4,152 (0%) | 0% | 225.9 | 45,848 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.78 per share. | 04 Feb 2021 | 154 | 4,355 (0%) | 0% | 223.8 | 34,462 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 4,600 | 4,600 | - | - | Non-qualified Stock Options | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 1,330 | 7,831 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Sale of securities on an exchange or to another person at price $ 214.59 per share. | 06 Nov 2020 | 588 | 3,949 (0%) | 0% | 214.6 | 126,179 | Common Stock |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2020 | 2,010 | 5,372 (0%) | 0% | - | Common Stock | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2020 | 2,010 | 6,501 | - | - | Restricted Stock Unit | |
| Labcorp | Mark Schroeder | EVP, President-Diagnostics Lab | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.42 per share. | 05 Nov 2020 | 835 | 4,537 (0%) | 0% | 214.4 | 179,041 | Common Stock |